NPM1 and neoplasm: Conversely, gene therapy could potentially lead to immune escape of the tumor by HLA class I down-regulation or loss of antigen expression, even though this latter may not be a limitation clearly relevant to NPM1 mutations, which are driver lesions essential for leukemogenesis and stably present in leukemic cells throughout the course of the disease [20].